Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma

Journal of Clinical Pathology

Volumn 69, Issue 3, 2016, Pages 234-239

  Lukenda, Adrian ^a   Dotlic, Snjezana ^b   Vukojevic, Nenad ^b   Saric, Borna ^c   Vranic, Semir ^d   Zarkovic, Kamelija ^e  

^a Ocna Poliklinika Opto Centar   (Croatia)

^b KBC Zagreb   (Croatia)

^c University Hospital Sveti Duh   (Croatia)

^d UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 9 ETHYLCARBAZOLE; CARBAZOLE DERIVATIVE; CD15 ANTIGEN; CD20 ANTIGEN; DIAMINOBENZIDINE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; FUCOSYLTRANSFERASE; FUT4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CHOROID MELANOMA; CILIARY BODY MELANOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EMBEDDING; ENUCLEATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UVEA MELANOMA; VERY ELDERLY; CHOROID NEOPLASMS; CILIARY BODY; DISEASE COURSE; ENZYMOLOGY; EVALUATION STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION; UVEAL NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD15; BIOMARKERS, TUMOR; CHOROID NEOPLASMS; CILIARY BODY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FUCOSYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASTIC STEM CELLS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; UVEAL NEOPLASMS;

EID: 84959337391     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-203130     Document Type: Article

References (26)

1. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:956-61.
2. Bergman L, Seregard S, Nilsson B, et al. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 2002;43:2579-83.
3. Willson JK, Albert DM, Diener-West M, et al. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119:670-6.
4. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-9.
5. Henderson E, Margo CE. Iris melanoma. Arch Pathol Lab Med 2008;132:268-72.
6. Kalirai H, Damato BE, Coupland SE. Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Invest Ophthalmol Vis Sci 2011;52:8458-66.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
8. Schmidt P, Abken H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011;2:313-20.
9. Dahlrot RH, Hermansen SK, Hansen S, et al. What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol 2013;6:334-48.
10. Stuelten CH, Mertins SD, Busch JI, et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 2010;28:649-60.
11. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005;13:205-20.
12. Mouriaux F, Kherrouche Z, Maurage CA, et al. Expression of the c-kit receptor in choroidal melanomas. Melanoma Res 2003;13:161-6.
13. All-Ericsson C, Girnita L, Müller-Brunotte A, et al. C-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci 2004;45:2075-82.
14. Wallander ML, Layfield LJ, Emerson LL, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol 2011;24:1031-5.
15. Pache M, Glatz K, Bösch D, et al. Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003;443:741-4.
16. Lüke J, Wegner J, Wegner R, et al. Expression of c-Kit and its ligand SCF in primary uveal melanoma. Eur J Ophthalmol 2011;21:615-24.
17. Machida E, Nakayama J, Amano J, et al. Clinicopathological significance of core 2 beta1, 6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization. Cancer Res. 2001;61:2226-31.
18. Breza TS, Magro CM. CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype. J Cutan Pathol 2005;32:685-9.
19. McLean IW, Foster WD, Zimmerman LE, et al. Modifications of Callender's classifications of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
20. Sanderson T, Zardin G. Immunohistochemistry quality control. In: Suvarna KS, eds. Bancroft's theory and practice of histological techniques: expert consult: online and print. Edinburgh: Churchill Livingstone, 2012:435-55.
21. Ferringer T. Skin. In: Lin F, Prichard JW, Liu H, Wilkerson M, Schuerch C, eds. Handbook of practical immunohistochemistry: frequently asked questions. New York, NY: Springer, 2011:524.
22. Zhao F, Chen Y, Wu Q, et al. Prognostic value of CD117 in cancer: a meta-analysis. Int J Clin Exp Pathol 2014;7:1012-21.
23. Petrausch U, Martus P, Tönnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008;22:997-1007.
24. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883-90.
25. De Wit NJ, van Muijen GN, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology 2004;44:517-41.
26. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119:1596-603.